William Finlay

William Finlay is currently the President of the LockBody Program at Centessa Pharmaceuticals and has served as the Founder and CEO of LockBody Therapeutics, a Centessa company, until 2023. With a strong background in drug discovery and protein engineering, they have also held significant roles such as Director at Pfizer and a Senior Post-Doctoral Researcher at Dublin City University. In addition to their leadership positions, they co-founded Granular Therapeutics and Ottimo Pharma, where they serve as Co-Founder and Advisor, respectively. Since 2015, they have contributed as an Associate Editor for mAbs Journal and have been involved with various scientific advisory boards, including Scholar Rock. William holds a PhD in Microbiology and Biochemistry from Glasgow Caledonian University.